TY - JOUR
T1 - Anaplastic astrocytoma in adults
AU - Stupp, Roger
AU - Reni, Michele
AU - Gatta, Gemma
AU - Mazza, Elena
AU - Vecht, Charles
PY - 2007/7/1
Y1 - 2007/7/1
N2 - Anaplastic astrocytoma is an uncommon disease in the adult population. Prognosis is influenced by age, symptom duration, mental status and Karnofsky performance status. A truly complete resection, which is a recognized independent prognostic factor, is not possible and recurrence in the surgical cavity is common. Based on randomized data available, chemotherapy has consistently failed to improve the outcome of patients with anaplastic astrocytoma, while a meta-analysis showed a small, but significant improvement in survival favouring the use of chemotherapy. Outside a clinical trial, postoperative radiotherapy (30 × 2 Gy) remains the standard adjuvant therapy for most patients. For elderly patients, the application of treatment is usually based on performance status and neurological function. In recurrent disease, chemotherapy with temozolomide has been proven to be active and well-tolerated in phase II trials, but no comparative phase III trials of other cytotoxic drugs have been conducted.
AB - Anaplastic astrocytoma is an uncommon disease in the adult population. Prognosis is influenced by age, symptom duration, mental status and Karnofsky performance status. A truly complete resection, which is a recognized independent prognostic factor, is not possible and recurrence in the surgical cavity is common. Based on randomized data available, chemotherapy has consistently failed to improve the outcome of patients with anaplastic astrocytoma, while a meta-analysis showed a small, but significant improvement in survival favouring the use of chemotherapy. Outside a clinical trial, postoperative radiotherapy (30 × 2 Gy) remains the standard adjuvant therapy for most patients. For elderly patients, the application of treatment is usually based on performance status and neurological function. In recurrent disease, chemotherapy with temozolomide has been proven to be active and well-tolerated in phase II trials, but no comparative phase III trials of other cytotoxic drugs have been conducted.
KW - Anaplastic astrocytoma
KW - Chemotherapy
KW - Cytotoxic drugs
UR - http://www.scopus.com/inward/record.url?scp=34249285571&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34249285571&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2007.03.003
DO - 10.1016/j.critrevonc.2007.03.003
M3 - Review article
C2 - 17478095
AN - SCOPUS:34249285571
VL - 63
SP - 72
EP - 80
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
SN - 1040-8428
IS - 1
ER -